Moderna’s COVID-19 vaccine shows efficacy of 94.5% in Phase 3 trial
Moderna announced its vaccine candidate against COVID-19 named mRNA-1273, has met Phase 3 study statistical criteria with a vaccine efficacy
Read more
RNA
Pfizer & BioNTech to supply EU with 200 million COVID-19 vaccine doses
Pfizer and BioNTech announced this week that they have reached an agreement with the European Commission to supply 200 million
Read more
Pfizer and BioNTech announce important COVID-19 vaccine breakthrough
Pfizer and BioNTech have announced their mRNA-based vaccine candidate for COVID-19, tested in a Phase 3 study involving 43,538 participants,
Read more
GMP Certified mRNA Manufacturing Site, BioNTech, Marburg, Germany
Next-gen immunotherapy company BioNTech announced this month the completion of a share purchase agreement with Swiss pharma giant Novartis AG,
Read more
Moderna’s mRNA COVID-19 vaccine generates antibodies in Phase I trial
Moderna’s COVID-19 vaccine candidate generated antibodies in all 45 patients studied in its early stage human trial, the U.S biotech
Read more
Tesla to help COVID-19 vaccine developer CureVac with molecule printers
Tesla Inc is engineering mobile molecule printers to help produce the future COVID-19 vaccine developed by CureVac in Germany, the
Read more
Moderna and Lonza partner up to manufacture COVID-19 vaccine
Moderna, a clinical-stage biotech developing messenger RNA (mRNA) therapeutics and vaccines, and Swiss pharma giant Lonza today announced the introduction
Read more
Intermediate analysis of Moderna’s Phase I Zika Vaccine (mRNA-1893)
The first intermediate analysis of the Phase I Zika vaccine candidate sample (mRNA-1893) reveals that the dosage levels of 10
Read more
Grange Castle Biotechnology Plant, Pfizer, Clondalkin, Ireland
Grange Castle Biotechnology Plant is one of the biggest integrated biotechnology plants in the world. Owned by the world-leading biotech
Read more